پزشکی فردی: تحولی جدید در مراقبت از بیمار به سمت پیش بینی و پیشگیری

[1]. Bauer, C., Stec, K., Glintschert, A., Gruden, K., Schichor, C., Or-Guil, M., Selbig, J., Schuchhardt, J. (2015). BioMiner: Paving the Way for Personalized Medicine. Cancer Inform. Vol.14, PP. 55-63.
[2].Agrawal, S. and Khan, F. (2007). Human genetic variation and personalized medicine. Indian J Physiol Pharmacol, Vol.51, No.1. PP. 7-28.
[3].Strachan, T. (2011). Human molecular genetics. 4th Ed. Garland Science Publisher, New York, USA, pp. 605- 608.
[4].Chen, R., Snyder, M. (2012). Systems biology: personalized medicine for the future? Current opinion in pharmacology, Vol. 12, No.5. PP. 623-628.
[5].Silverman, R.B., (1992. (The Organic Chemistry of Drug Design and Drug Action, Academic Press, New York, USA, pp. 277-351.
[6].Horai, Y., Nakano, M., Ishizaki, T., Zhou, H. H., Zhou, B. J., Liao, C. L., Zhang, L. M. (1989). Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther, Vol. 46, No.2. PP. 198-207.
[7].Jurima, M., Inaba, T., Kadar, D., Kalow, W. (1985). Genetic polymorphism of mephenytoin p(4’)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol, Vol.19, PP. 483-487.
[8].Ginsburg, G. S., Willard, H. F., (2009). Genomic and personalized medicine: foundations and applications. Transl Res. Vol. 154, PP. 277–287.
[9].Martin-Sanchez, F., Iakovidis, I., Norager, S., Maojo, V., De Groen, P., Van der Lei, J., Jones, T., Abraham- Fuchs, K., Apweiler, R., Babic, A., Baud, R., Breton, V., Cinquin, P., Doupi, P., Dugas, M., Eils, R., Engelbrecht, R., Ghazal, P., Jehenson, P., Kulikowski, C., Lampe, K., De Moor, G., Orphanoudakis, S., Rossing, N., Sarachan, B., Sousa, A., Spekowius, G., Thireos, G., Zahlmann, G., Zvárová, J., Hermosilla, I., Vicente, F. J., (2004). Synergy between medical informatics and bioinformatics: facilitating genomic medicine for future health care. Journal of Biomedical Informatics, Vol.37, PP. 30-42.
[10].Lopes, P., Arrais, J., Oliveira J. L. (2012). Bioinformatics for Personalized Medicine: A Holistic Approach for Integrating Genomic Variation Information, Springer, Berlin, Germany, PP. 42-49.
[11]. Ginsburg, G. S., Donahue, M., (2005). Prospects for personalized cardiovascular medicine: the impact of genomics. J Am Coll Cardiology, Vol.46, No.9. PP. 1615-1627.
[12]. Ziegler, A., Koch, A., Krockenberger, K., Grobhennig, A. (2012). Personalized medicine using DNA biomarkers: a review. Human Genetics, Vol.131, No.10. PP. 1627-1638.
[13].Ganesalingam, J., Bowser, R. (2010). The application of biomarkers in clinical trials for motor neuron disease. Biomark Med., Vol.4, No.2. PP. 281–297.
[14].Diamandis, E.P. (2012). Biomarker validation is still the bottleneck in biomarker research. Journal of Internal Medicine, Vol.272, No.6. PP. 620-631.
[15].Lohmann, S., Lehmann, L., Tabiti Roche, K. (2000). Fast and Flexible Single Nucleotide Polymorphism (SNP) Detection with the Light Cycler System. Biochemica, Vol.4, PP. 23-28.
[16].Gupta, R., Kim, J.P., Spiegel, J., Ferguson, S.M. (2004). Developing products for personalized medicine: NIH Research Tools Policy applications. Per Med, Vol.1, No.1. PP. 115-124.
[17].Luzi, L. (2012). Cellular physiology and metabolism of physical exercise, Springer, Verlag, Italia, PP. 548-573.
[18].Marez, D., Legrand, M., Sabbagh, N., Guidice, J. L., Spire, C., Lafitte, J. J. (1997). Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics, Vol.7, No.3. PP. 193-202.
[19].Klonoff, D. C. (2009). The personalized medicine for diabetes meeting summary report. Journal of Diabetes Sci Technol, Vol.3, No.4. PP. 677-679.
[20].International HapMap, C. (2007). A second generation human haplotype map of over 3.1 million SNPs. Nature, Vol.449, No.7164. PP. 851-861.
[21].Jain, K. K. (2004). Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics, Vol.5, No.3. PP. 331-336.
[22]. Bencharit S. (2012). Progresses and challenges of omics studies and their impacts in personalized medicine. J Pharmacogenomics Pharmacoproteomics, Vol.3, No.1. PP. 115-124.
[23].Xie, H., Frueh, F.W. (2005). Pharmacogenomics steps toward personalized medicine. Personalized Medicine, Vol.2, No.4. PP. 325-337.
[24].Gieger, C., Geistlinger, L., Altmaier, E., Hrabé de Angelis, M., Kronenberg, F., Meitinger, T., Mewes, H. W., Wichmann, H. E., Weinberger, K. M., Adamski, J., Illig, T., Suhre, K. (2008). Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet, Vol.4, No.11. PP. e1000282.
[25]. Monte, A. A., Brocker, C., Nebert, D. W., Gonzalez, F. J., Thompson, D. C., Vasiliou, V. (2014). Improved drug therapy: triangulating phenomics with genomics and metabolomics. Hum Genomics, Vol.8, No.1. PP. 16-25.
[26].Ginsburg, G. S., Willard, H. F. (2009). Genomic and personalized medicine: foundations and applications. Transl res., Vol.154, No.6. PP. 277-287.
[27].Ginsburg, G. S., McCarthy, J. J. (2001). Personalized medicine: revolutionizing drug discovery and patient care. Trends in Biotechnology, Vol.19, No.12. PP. 491-496.
[28].Abrahams, E., Silver, M. (2009). The case for personalized medicine. J of Diabetes Sci Technol, Vol.3, No.4. PP. 680-684.
[29].Piccart-Gebhart, M. J., Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C. H., Steger, G., Huang, C. S., Andersson, M., Inbar, M., Lichinitser, M., Lang, I., Nitz, U., Iwata, H., Thomssen, C., Lohrisch, C., Suter, T. M., Ruschoff, J., Suto, T., Greatorex, V., Ward, C., Straehle, C., McFadden, E., Dolci, M. S., Gelber, R. D., Herceptin Adjuvant Trial Study Team, (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, Vol.353, No.16. PP. 1659-1672.
[30].Yamamoto, F., Cid, E., Yamamoto, M., Blancher, A. (2012). ABO research in the modern era of genomics. Transfus Med Rev, Vol.26, No. 2. PP. 103-118.
[31].Liumbruno, G. M., Franchini M. (2013). Beyond immunohaematology: the role of the ABO blood group in human diseases. Blood Transfus, Vol.11, No.4. PP. 491-499.
[32].He, M., Wolpin, B., Rexrode, K., Manson, J. E., Rimm, E., Hu, F. B., Qi, L. (2012). ABO blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol, Vol.32, No.9. PP. 2314-2320.
[33].Franchini, M., Mannucci, P. M. (2014). ABO blood group and thrombotic vascular disease. Thromb Haemost, Vol.112, No.6. PP. 1103-1109.
[34].Iodice, S., Maisonneuve, P., Botteri, E., Sandri, M. T., Lowenfels, A.B. (2010). ABO blood group and cancer. Eur J Cancer, Vol.46, No.18. PP. 3345-3350.
[35].Liumbruno, G. M., Franchini, M. (2014). Hemostasis, cancer, and ABO blood group: the most recent evidence of association. J Thromb Thrombolysis, Vol.38, No.2. PP. 160-166.
[36].Etemadi, A., Kamangar, F., Islami, F., Poustchi, H., Pourshams, A., Brennan, P., Boffetta, P., Malekzadeh, R., Dawsey, S. M., Abnet, C. C., Emadi, A. (2015). Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study. BMC Med, Vol.13, No.5. PP. 8-20.
[37].Au, N., Rettie, A. E. (2008). Pharmacogenomics of 4-hydroxycoumarin anticoagulants. Drug Metab Rev, Vol.40, No.2. PP. 355-75.
[38].Rieder, M. J., Reiner, A. P., Gage, B. F. (2005). Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, Vol.352, No.22. PP. 2285-93.
[39].Singh, O., Sandanaraj, E., Subramanian, K., Lee, L. H., Chowbay, B. (2011). Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab Pharmacokinet, Vol.26, No.2. PP. 130-136.
[40].Caldwell, M. D., Awad, T., Johnson, J. A. (2008). CYP4F2 genetic variant alters required warfarin dose. Blood, Vol.111, No.8. PP. 4106-4112.
[41].Takeuchi, F., McGinnis, R., Bourgeois, S. (2009). A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet, Vol.5, No.3. PP. e1000433.
[42].Cooper, G. M., Johnson J. A., Langaee T. Y. (2008). A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood, Vol.112, No.4. PP. 1022-1027.
[43].Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Hogg, D. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England. Journal of Medicine, Vol.364, No.26. PP. 2507-2516.
[44].Ellard, S., Colclough, K. (2006). Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum Mutat, Vol.27, No.9. PP. 854-869.
[45].Jia, W. (2013). Personalized medicine of type 2 diabetes. Front Med, Vol.7, No.1. PP. 1-10.
[46].McCarthy, M. I. (2010). Genomics, type 2 diabetes, and obesity. New England Journal of Medicine, Vol.363, No.24. PP. 2339-2350.
[47]. Zhou, M., Xia, L., Wang J. (2007). Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos, Vol.35, No.10. PP. 1956-1962.
[48]. Kimura, N., Masuda, S., Tanihara, Y. (2005). Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet, Vol.20, No.9. PP. 379–386.
[49]. Shu, Y., Sheardown, S. A., Brown, C. (2007). Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest, Vol.117, No.5. PP. 1422-1431.
[50]. Pearson, E. R., Pruhova, S., Tack, C. J., Johansen, A., Castleden, H. A., Lumb, P.J., Wierzbicki, A. S., Clark, P. M., Lebl, J., Pedersen, O., Ellard, S., Hansen, T., Hattersley, A. T. (2005). Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia, Vol.48, No.5. PP. 878-885.
[51].Shepherd, M., Pearson, E. R., Houghton, J., Salt, G., Ellard, S., Hattersley, A. T. (2003). No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care, Vol.26, No.5. PP. 3191–3192.
[52]. Shepherd, M., Hattersley, A. T. (2004). I don’t feel like a diabetic any more: the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Clin Med, Vol.4, No.8. PP. 144-147.
[53].Raciti, GA., Nigro, C., Longo, M. (2014). Personalized medicine and type 2 diabetes: lesson from epigenetics. Epigenomics, Vol.6, No.2. PP. 229-38.
[54].Manolopoulos, V. G., Ragia, G., Tavridou, A. (2011). Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics, Vol.12, No.8. PP. 1161–1191.
[55].Caporali, A., Meloni, M., Völlenkle, C. (2011). Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation, Vol.123, No.3. PP. 282–291.
[56].Lares, M. R., Rossi, J. J., Ouellet, D. L. (2010). RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol, Vol.28, No.11. PP. 570–579.
[57].Qiu, C., Kivipelto, M., Strauss, E. (2009). Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci, Vol.11, PP. 111–128.
[58].Esteban-Santillan, C., Praditsuwan, R., Ueda, H., Geldmacher, D. S. (1998). Clock drawing test in very mild Alzheimer’s disease. J Am Geriatr Soc., Vol.46, No.10. PP. 1266-1269.
[59].Qin, W., Ho, L., Wang, J., Peskind E, Pasinetti GM, (2009). A novel Alzheimer’s disease biomarker with nonamyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One, Vol.4, No.1. PP. e4183.
[60].Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Hoyte, K. (2012). A mutation in APP protects against Alzheimer/’s disease and age-related cognitive decline. Nature, Vol.488, No.7409. PP. 96-99.
[61].Jain, K. K. (2009). Textbook of personalized medicin, Springer, New York, USA, PP. 205-225.
[62].Jain, K.K. (2006). A critical review of the Royal Society’s report on personalized medicine. Drug Discov Today, Vol.11, No.13-14. PP. 573–575.
[63].Regierer, B., Zazzu, V., Sudbrak, R., Kühn, A., Lehrach, H. (2013). Future of medicine: models in predictive diagnostics and personalized medicine. Adv Biochem Eng Biotechnol, Vol.133, PP. 15-33.
[64].Baer-Dubowska, W., Majchrzak-Celińska, A., & Cichocki, M. (2011). Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacological Reports, Vol.63, No.2. PP. 293-304.
[65].Gomez, A., Ingelman‐Sundberg, M. (2009). Pharmacoepigenetics: its role in interindividual differences in drug response. Clinical Pharmacology & Therapeutics, Vol.85, No.4. PP. 426-430.
[66].Souslova, T., Marple, T. C., Spiekerman, A. M., Mohammad, A. A. (2013). Personalized medicine in Alzheimer’s disease and depression. Contemporary clinical trials, Vol.36, No.2. PP. 616-623.
[67].Lesko, L. J. (2007). Personalized medicine: elusive dream or imminent reality? Clinical Pharmacology & Therapeutics, Vol.81, No.6. PP. 807-816.
[68].Gonzalez de Castro, D., Clarke, P. A., AlLazikani, B., Workman, P. (2013). Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clinical Pharmacology & Therapeutics, Vol.93, No.3. PP. 252-259
[69]. ناصر پارسا ، فاطمه قمری و علی اکبر موسوی موحدی، "تبدیل تحقیقات علوم پایه به روش های درمانی: رقابتی علمی و جدید در سطح جهانی"، نشریه نشا علم، مجلد۳، شماره ۲، صفحات ۱۲۲-۱۲۷، سال ۱۳۹۲.